scholarly journals Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates

2020 ◽  
Vol 4 (2) ◽  
pp. 205-216 ◽  
Author(s):  
Michael Wallisch ◽  
Christina U. Lorentz ◽  
Hari H. S. Lakshmanan ◽  
Jennifer Johnson ◽  
Marschelle R. Carris ◽  
...  
Keyword(s):  
Nonhuman Primates ◽  
Factor Xii ◽  
Membrane Oxygenator ◽  
Extracorporeal Membrane Oxygenator ◽  
Platelet Deposition ◽  
Antibody Inhibition

scholarly journals Goodpasture's-Like Syndrome and Effect of Extracorporeal Membrane Oxygenator Support.

1994 ◽  
Vol 33 (9) ◽  
pp. 569-573 ◽  
Author(s):  
Shoichiro DAIMON ◽  
Tomoya UMEDA ◽  
Ichiro Ichiro MICHISHITA ◽  
Harue WAKASUGI ◽  
Akira GENDA ◽  
...  
Keyword(s):  
Membrane Oxygenator ◽  
Extracorporeal Membrane Oxygenator

Comparison of outcomes of infants with giant omphaloceles over two decades

2020 ◽  
pp. 1-5
Author(s):  
R.E. Witt ◽  
M. Singhal ◽  
A.J. Vachharajani
Keyword(s):  
Mechanical Ventilation ◽  
Medical Records ◽  
Invasive Mechanical Ventilation ◽  
Informed Decision Making ◽  
Membrane Oxygenator ◽  
Associated Anomalies ◽  
Single Institution ◽  
Extracorporeal Membrane Oxygenator ◽  
Pulmonary Vasodilators ◽  
Improved Outcomes

BACKGROUND: The purpose of this study was to compare the outcomes of infants with giant omphalocele (GO) born in two different epochs over two decades at a single institution. Specifically, it examined whether the utilization of selective pulmonary vasodilators and extracorporeal membrane oxygenator (ECMO) in the management of pulmonary hypertension in the second epoch were associated with improved outcomes. METHODS: The medical records of all patients diagnosed with GO at a large children’s hospital from January 1, 1996 to December 31, 2016 were reviewed and divided into two epochs. Patients were classified as having an isolated GO or GO with minor or major associated anomalies. GO was defined as a defect more than or equal to 5 cm in size and/or liver in the sac. RESULTS: During the study period, 59 infants with GO were identified. The duration of invasive mechanical ventilation was significantly shorter among the survivors from the second epoch (p = 0.03), with none greater than seven days. There were no significant differences in the outcomes of survival to NICU discharge and length of stay (LOS) between infants in the two epochs. CONCLUSIONS: Infants with GO who required invasive mechanical ventilation for more than seven days did not survive in the second epoch. Survival did not improve with uses of selective pulmonary vasodilators and ECMO. This information could be shared with families during prenatal and postnatal counselling to facilitate informed decision making regarding goals of care.

Levosimendan in veno‐arterial extracorporeal membrane oxygenator supported patients: impact on the success of weaning and survival

2020 ◽  
Author(s):  
Marta Alonso‐Fernandez‐Gatta ◽  
Soraya Merchan‐Gomez ◽  
Miryam Gonzalez‐Cebrian ◽  
Alejandro Diego‐Nieto ◽  
Elisabete Alzola ◽  
...  
Keyword(s):  
Membrane Oxygenator ◽  
Extracorporeal Membrane Oxygenator

A Miniaturized Extracorporeal Membrane Oxygenator with Integrated Rotary Blood Pump: Preclinical In Vivo Testing

ASAIO Journal ◽  
2011 ◽  
Vol 57 (3) ◽  
pp. 158-163 ◽  
Author(s):  
Ruedger Kopp ◽  
Ralf Bensberg ◽  
Jutta Arens ◽  
Ulrich Steinseifer ◽  
Thomas Schmitz-Rode ◽  
...  
Keyword(s):  
Blood Pump ◽  
Membrane Oxygenator ◽  
Rotary Blood Pump ◽  
Extracorporeal Membrane Oxygenator ◽  
In Vivo Testing

scholarly journals Decontamination of Extracorporeal Membrane Oxygenator Devices With an Intensified Disinfection Protocol: How Strict Is Too Strict?

2018 ◽  
Vol 39 (3) ◽  
pp. 366-367 ◽  
Author(s):  
Rami Sommerstein ◽  
Tobias M. Merz ◽  
Stephan M. Jakob ◽  
Jukka Takala ◽  
Jonas Marschall
Keyword(s):  
Membrane Oxygenator ◽  
Extracorporeal Membrane Oxygenator

Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator

2020 ◽  
pp. 106002802096040
Author(s):  
Abdulrazaq Al-Jazairi ◽  
Shahad Raslan ◽  
Rayd Al-mehizia ◽  
Hani Al Dalaty ◽  
Edward B. De Vol ◽  
...  
Keyword(s):  
Unfractionated Heparin ◽  
Tertiary Care ◽  
Factor Xa ◽  
Controlled Study ◽  
Care Hospital ◽  
Strong Correlations ◽  
Membrane Oxygenator ◽  
Monitoring Methods ◽  
Extracorporeal Membrane Oxygenator ◽  
Hospital Patients

Background The use of extracorporeal membrane oxygenator (ECMO) support devices are associated with complications, including bleeding and thrombosis. Unfractionated heparin (UFH) is the gold standard anticoagulant in ECMO patients. Clinically, UFH is monitored through activated clotting time (ACT), activated partial thromboplastin time (aPTT), and anti–factor Xa assay. It is unknown which assay best predicts anticoagulation effects in adults. Objective To assess the correlation of UFH dosing and monitoring using an established protocol. Methods A pilot, prospective cohort, historically controlled study was conducted at a tertiary care hospital. Patients ≥18 years-old who received ECMO on the multifaceted anticoagulation protocol were included and compared with those on the conventional method of anticoagulation. The primary end point was to assess the correlation between UFH dose and different monitoring methods throughout 72 hours using the new protocol guided by ACT and anti–factor Xa assay. Results In each arm, 20 patients were enrolled. The study revealed that anti–factor Xa assay had the largest number of “strong” correlations 11/20 (55%), followed by both aPTT and aPTT ratio 10/20 (50%), and, finally, ACT 2/20 (10%). Concordance between anti–factor Xa assay and the other monitoring parameters in the prospective arm was generally low: 31% with aPTT ratio, 26% with ACT, and 23% with aPTT. Conclusion and Relevance The adaption of a multifaceted anticoagulation protocol using anti–factor Xa assay may provide a better prediction of heparin dosing in adults ECMO patients compared with the conventional ACT-based protocol. Further studies are needed to assess the safety and different monitoring modalities.

Use of Extracorporeal Membrane Oxygenator in Massive Pulmonary Embolism

2019 ◽  
Vol 72 (9) ◽  
pp. 793-794
Author(s):  
Raquel Luna-López ◽  
Iago Sousa-Casasnovas ◽  
Jorge García-Carreño ◽  
Carolina Devesa-Cordero ◽  
Francisco Fernández-Avilés ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Massive Pulmonary Embolism ◽  
Membrane Oxygenator ◽  
Extracorporeal Membrane Oxygenator
Sign in / Sign up

Export Citation Format

Share Document